Calidi Biotherapeutics, Inc. (CLDI)
1.12
+0.02
(+1.82%)
USD |
NYAM |
Sep 21, 16:00
1.18
+0.06
(+5.36%)
After-Hours: 20:00
Calidi Biotherapeutics Debt to Equity Ratio : 0.6199 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6199 |
| March 31, 2026 | 0.4573 |
| December 31, 2025 | 0.6821 |
| September 30, 2025 | 0.4782 |
| June 30, 2025 | 2.274 |
| March 31, 2025 | 0.6779 |
| December 31, 2024 | 4.587 |
| September 30, 2024 | -0.8774 |
| June 30, 2024 | -0.7432 |
| March 31, 2024 | -0.8037 |
| December 31, 2023 | -0.8787 |
| Date | Value |
|---|---|
| September 30, 2023 | -8.912 |
| June 30, 2023 | 0.0477 |
| March 31, 2023 | 0.0418 |
| December 31, 2022 | -0.1466 |
| September 30, 2022 | 0.0145 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -3.238 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 7.204M |
| Total Liabilities (Quarterly) | 4.071M |
| Shareholders Equity (Quarterly) | 3.133M |
| Current Ratio | 1.677 |
| Net Debt Paydown Yield | 9.76% |